MedTrace Logo

Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors

NCT02688101 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-02-21

No results posted yet for this study

Summary

Multicenter, open-label, dose-escalation and pharmacokinetic study.

Conditions

  • Neoplasms

Interventions

DRUG

DpC

iron chelator

Sponsors & Collaborators

  • Collaborative Medicinal Development Pty Limited

    lead INDUSTRY

Principal Investigators

  • Linda Mileshkin, MD · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2017-10-26
Completion
2017-10-26

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02688101 on ClinicalTrials.gov